Ilayda Altinönder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ilayda Altinönder has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Maria Schwarz
Nutritional Physiology, Institute of Nutritional Sciences, Friedrich-Schiller-University Jena, Dornburger Straße 24, 07743 Jena, Germany
2 shared publications Nadia Gul
Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden
2 shared publicationsAhmed Ezat El Zowalaty
Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden
1 shared publication- Alina Löser
Nutritional Physiology, Institute of Nutritional Sciences, Friedrich-Schiller-University Jena, Dornburger Straße 24, 07743 Jena, Germany
1 shared publication - Anders Ståhlberg
Department of Laboratory Medicine, Sahlgrenska Center for Cancer Research, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
1 shared publication Andreas Hallqvist
Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
1 shared publication
Latest Publications
- Open Access
- 4 November 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (11) , 2924-2937
Longitudinal single-cell profiling of breast tumors highlights immune and epigenetic mechanisms associated with sensitivity to aromatase inhibitors
- 4 November 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (11) , 2924-2937
Open AccessLongitudinal single-cell profiling of breast tumors highlights immune and epigenetic mechanisms associated with sensitivity to aromatase inhibitors
- Top Cited PapersOpen Access
- 11 March 2026
- Published by Springer Nature in Nature
- Vol. 652 (8112) , 1339-1348
Ageing promotes metastasis via activation of the integrated stress response
Lung cancer predominantly affects older individuals, yet how physiological ageing influences tumour evolution remains poorly understood 1 . Here we show that ageing reprograms the evolutionary trajectory of KRAS -driven lung adenocarcinoma, limiting primary tumour growth while promoting metastatic dissemination through epigenetic activation of the integrated stress response (ISR). The ISR effector ATF4 drives epithelial and metabolic plasticity, conferring metastatic competence. Mechanistically, aged tumour cells show increased sensitivity to the PERK–eIF2α arm of the unfolded protein response, sustaining persistent ATF4 signalling. Targeting ISR–ATF4 genetically or pharmacologically abolishes these adaptations and limits dissemination, whereas ATF4 overexpression alone is sufficient to induce metastasis. The ageing–ATF4 axis imposes a dependency on glutamine metabolism, revealing a therapeutically actionable vulnerability. Clinical analyses confirm that ATF4 is enriched in aged tumours and correlates with poor survival and advanced-stage disease. Collectively, these results define epigenetic ISR–ATF4 activation as a causal driver of lineage plasticity and metastasis in aged tumours, revealing a therapeutic opportunity in older patients with lung adenocarcinoma, the most common yet understudied subset of lung cancer.
- 11 March 2026
- Published by Springer Nature in Nature
- Vol. 652 (8112) , 1339-1348
Top Cited PapersOpen AccessAgeing promotes metastasis via activation of the integrated stress response
Lung cancer predominantly affects older individuals, yet how physiological ageing influences tumour evolution remains poorly understood 1 . Here we show that ageing reprograms the evolutionary trajectory of KRAS -driven lung adenocarcinoma, limiting primary tumour growth while promoting metastatic dissemination through epigenetic activation of the integrated stress response (ISR). The ISR effector ATF4 drives epithelial and metabolic plasticity, conferring metastatic competence. Mechanistically, aged tumour cells show increased sensitivity to the PERK–eIF2α arm of the unfolded protein response, sustaining persistent ATF4 signalling. Targeting ISR–ATF4 genetically or pharmacologically abolishes these adaptations and limits dissemination, whereas ATF4 overexpression alone is sufficient to induce metastasis. The ageing–ATF4 axis imposes a dependency on glutamine metabolism, revealing a therapeutically actionable vulnerability. Clinical analyses confirm that ATF4 is enriched in aged tumours and correlates with poor survival and advanced-stage disease. Collectively, these results define epigenetic ISR–ATF4 activation as a causal driver of lineage plasticity and metastasis in aged tumours, revealing a therapeutic opportunity in older patients with lung adenocarcinoma, the most common yet understudied subset of lung cancer.
- Open Access
- 13 June 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Excessive copper impairs intrahepatocyte trafficking and secretion of selenoprotein P
Selenium homeostasis depends on hepatic biosynthesis of selenoprotein P (SELENOP) and SELENOP-mediated transport from the liver to e.g. the brain. In addition, the liver maintains copper homeostasis. Selenium and copper metabolism are inversely regulated, as increasing copper and decreasing selenium levels are observed in blood during aging and inflammation. Here we show that copper treatment increased intracellular selenium and SELENOP in hepatocytes and decreased extracellular SELENOP levels. Hepatic accumulation of copper is a characteristic of Wilson’s disease. Accordingly, SELENOP levels were low in serum of Wilson’s disease patients and Wilson’s rats. Mechanistically, drugs targeting protein transport in the Golgi complex mimicked some of the effects observed, indicating a disrupting effect of excessive copper on intracellular SELENOP transport resulting in its accumulation in the late Golgi. Our data suggest that hepatic copper levels determine SELENOP release from the liver and may affect selenium transport to peripheral organs such as the brain.
- 13 June 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Open AccessExcessive copper impairs intrahepatocyte trafficking and secretion of selenoprotein P
Selenium homeostasis depends on hepatic biosynthesis of selenoprotein P (SELENOP) and SELENOP-mediated transport from the liver to e.g. the brain. In addition, the liver maintains copper homeostasis. Selenium and copper metabolism are inversely regulated, as increasing copper and decreasing selenium levels are observed in blood during aging and inflammation. Here we show that copper treatment increased intracellular selenium and SELENOP in hepatocytes and decreased extracellular SELENOP levels. Hepatic accumulation of copper is a characteristic of Wilson’s disease. Accordingly, SELENOP levels were low in serum of Wilson’s disease patients and Wilson’s rats. Mechanistically, drugs targeting protein transport in the Golgi complex mimicked some of the effects observed, indicating a disrupting effect of excessive copper on intracellular SELENOP transport resulting in its accumulation in the late Golgi. Our data suggest that hepatic copper levels determine SELENOP release from the liver and may affect selenium transport to peripheral organs such as the brain.